Unveiling the Role of Lead Molecules in CADD: A Systematic Review

Year : 2024 | Volume :01 | Issue : 01 | Page : –
By

Satish kumar Yadav

  1. Associate professor, Dept. of Pharmacy Prasad Institute of Technology, Jaunpur Uttar Pradesh India

Abstract

The word “medicate plan” alludes to the objective creation of modern drugs. Arbitrary screening of engineered compounds, engineered of organically dynamic compounds based on actually happening drugs, amalgamation of basic analogs of actually happening lead particles, and usage of the bioisosteric hypothesis are a few of the strategies that have been utilized. As a result, the most recent drift in medicate plan is to either completely enhance a lead or enhance an existing lead. A driving atom is another title for a lead. The lead may be a model particle with the required natural or pharmacological movement, but it may too have a number of undesirable properties, such as tall poisonous quality, other natural exercises (side impacts), insolubility, or digestion system issues, which are straightforward to control once set up. This can be a decently clear method. The genuine challenge is recognizing such a lead particle and deciding the leading bioactive positions on its straightforward skeleton. Medicate revelation utilizes chemical science and computational medicate plan approaches for the proficient distinguishing proof and optimization of lead compounds. Chemical science is generally included within the illustration of the organic work of a target and the component of activity of a chemical modulator. As opposed to this, computer-supported medication plans use fundamental data from the target (structure-based) or from known ligands with bioactivity (ligand-based) in order to promote the development of prospective candidate medications. Different virtual screening methods are presently being utilized by both pharmaceutical companies and scholastic inquire about bunches to decrease the fetched and time required for the revelation of a strong sedate. In spite of the fast propels in these strategies, nonstop enhancements are basic for future medicate disclosure devices.

Keywords: Lead optimization, Bioisosteric hypothesis, Computational drug design, Virtual screening methods, Chemical science

[This article belongs to International Journal of Membranes(ijm)]

How to cite this article: Satish kumar Yadav. Unveiling the Role of Lead Molecules in CADD: A Systematic Review. International Journal of Membranes. 2024; 01(01):-.
How to cite this URL: Satish kumar Yadav. Unveiling the Role of Lead Molecules in CADD: A Systematic Review. International Journal of Membranes. 2024; 01(01):-. Available from: https://journals.stmjournals.com/ijm/article=2024/view=147767




References

  1. Phelps CE. Eight Questions You Should Ask About Our Health Care System:(Even if the Answers Make You Sick). Hoover Press; 2013 Sep 1.
  2. Chavda V, Thalkari Y, Marwadi S. New strategies in drug discovery. Computation in BioInformatics: Multidisciplinary Applications. 2021 Oct 28:25-48.
  3. Paul E, Liu Y, editors. Biological sludge minimization and biomaterials/bioenergy recovery technologies. Hoboken, NJ: Wiley; 2012 May 6.
  4. Curtin P, Stanwick J, Beddie F. About the research.
  5. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, Green DV, Hertzberg RP, Janzen WP, Paslay JW, Schopfer U. Impact of high-throughput screening in biomedical research. Nature reviews Drug discovery. 2011 Mar;10(3):188-95.
  6. Lionta E, Spyrou G, K Vassilatis D, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Current topics in medicinal chemistry. 2014 Aug 1;14(16):1923-38.
  7. Anderson AC. The process of structure-based drug design. Chemistry & biology. 2003; 10(9):787-97. 25. Hopfinger AJ. Computer-assisted drug design. Journal of medicinal chemistry. 1985; 28(9):1133-9.
  8. Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S (Jun 2006). “An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression”. Journal of Medicinal Chemistry. 49 (11): 3116–35. doi:10.1021/jm0508641. PMID 16722631.
  9. Salum LB, Andricopulo AD. Fragment-based QSAR: perspectives in drug design. Molecular diversity. 2009 Aug;13:277-85.
  10. Cavagnaro JA. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nature Reviews Drug Discovery. 2002 Jun 1;1(6):469-75.
  11. Burdine L, Kodadek T. Target identification in chemical genetics: the (often) missing link. Chemistry & biology. 2004 May 1;11(5):593-7.
  12. SiddiquiAnees Ahmad, Kumar Harish, KhisalSubuhi, “Computer-Aided Drug Design” CBS Publisher & Distributors. pp 12-14.
  13. Hughes JP., Rees S., Kalindjian SB., Philpott KL., (March 2011). “Principles of early drug discovery”. British Journal of Pharmacology. 162 (6):1239-1249. doi:10.1111/j.1476- 5381.2010.01127.x. PMC 3058157. PMID 21091654
  14. Von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nature reviews Drug discovery. 2007 Dec;6(12):967-74.
  15. Schneider, Gisbert (2013). “Prediction of Drug-Like Properties”. Landes Bioscience. Retrieved 20 November 2017.
  16. Larson RS (2006) Methods in Molecular Biology: Bioinformatics and Drug Discovery. Department of Pathology, University of New Mexico School of Medicine, Albuquerque, NM 1: 227-228.
  17. MartiRenom MA, Stuart AC, Fiser A, Sanchez R, Melo F And Sali A: Comparative protein structure modelling of Genes and genomes. Annual Review of Biophysics and Bio Molecular Structure 2000; 29(1): 291-325.
  18. Putz MV, Lacrămă AM. Introducing spectral structure activity relationship (S-SAR) analysis. Application to ecotoxicology. International Journal of Molecular Sciences. 2007 May 22;8(5):363-91.
  19. Gohlke H, Klebe G. DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. Journal of medicinal chemistry. 2002 Sep 12;45(19):4153-70.
  20. Lewis RA (2011). “Chapter 4: The Development of Molecular Modelling Programs: The Use and Limitations of Physical Models”. In Gramatica P, Livingstone DJ, Davis AM (eds.). Drug Design Strategies: Quantitative Approaches. RSC Drug Discovery. Royal Society of Chemistry. pp. 88– 107. doi:10.1039/9781849733410-00088. ISBN 978-1849731669.
  21. Boissel JP, Lee WR, Presnell SR, Cohen FE and Bunn HF: Erythropoietin structure-function relationships. Mutant Proteins that test a model of tertiary structure. Journal Of biological chemistry, 2013; 268(21):15983-15993.
  22. Macalino SJ, Gosu V, Hong S, Choi S. Role of computer-aided drug design in modern drug discovery. Archives of pharmacal research. 2015 Sep;38:1686-701.
  23. Yoo J, Choi S, Medina-Franco JL. Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs. PloS one. 2013 Apr 25;8(4):e62152.
Regular Issue Subscription Review Article
Volume 01
Issue 01
Received May 13, 2024
Accepted May 22, 2024
Published May 27, 2024
Views: 45